恶性疟原虫青蒿素和哌喹耐药的流行现状及机制研究进展

恶性疟原虫是全球范围内危害重大的寄生虫类传染病病原体之一。青蒿素是抗疟药的首选药物，目前已在多个国家和地区发现恶性疟原虫对青蒿素及其与哌喹联合用药耐受性。研究已经发现与青蒿素耐药性有关的基因突变，但哌喹耐药性的机制仍有待进一步研究。本文就近年恶性疟原虫对青蒿素及哌喹耐药的流行现状和分子机制研究进展作一综述。
Plasmodium falciparum is one of the main parasitic pathogens worldwide. Artemisinin derivatives are the first-line antimalarial drug. Recently, Plasmodium falciparum has been found to be tolerant to the treatment with artemisinin derivatives and its combination with piperaquine in several countries and regions. Scientists have found gene mutations associated with resistance of Plasmodium falciparum to artemisinin derivatives; however the mechanism of piperaquine resistance remains to be further studied. This review sums up the epidemic status and mechanism research of the resistance of Plasmodium falciparum to artemisinin derivatives and piperaquine